Andrew Scanga, MD
Transplant Hepatology · Nashville, TNNPI 1912016650
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,660 of the $44,846 with a category attached, or 88.4%. Madrigal Pharmaceuticals accounts for 99.3% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $33,465, more than ten times the $163 reported in 2022.
Across 35 payments — averaging $1281.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$45K
- Intercept Pharmaceuticals, Inc.$163
- Mirum Pharmaceuticals, Inc.$138
Across 125 payments — averaging $3723.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$211K
- Ultragenyx Pharmaceutical Inc.$87K
- Intercept Pharmaceuticals, Inc.$69K
- Bausch Health US, LLC$31K
- AbbVie$28K
- Ipsen Pharma SAS$24K
- plus $16K from 2 others
What the payments were for
- Speaking & faculty fees$39,66088%
- Travel & lodging$3,6818%
- Food & beverage$1,5063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 32 | $44,546 |
| Intercept Pharmaceuticals, Inc. | 2 | $163 |
| Mirum Pharmaceuticals, Inc. | 1 | $138 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few transplant hepatology providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 47 | $152,309 |
| Tacrolimus | 219 | $34,145 |
| VemlidyTenofovir Alafenamide | 14 | $19,424 |
| Sirolimus | 44 | $14,625 |
| Ursodiol | 61 | $11,426 |
| Mycophenolate Mofetil | 39 | $3,786 |
| Cyclosporine ModifiedCyclosporine, Modified | 12 | $2,748 |
| Lactulose | 30 | $1,663 |
| Tenofovir Disoproxil Fumarate | 12 | $1,141 |
| Azathioprine | 21 | $905 |
| Budesonide DrBudesonide | 11 | $743 |
| Spironolactone | 28 | $589 |
| Warfarin Sodium | 27 | $540 |
| Carvedilol | 70 | $466 |
| Omeprazole | 42 | $347 |
Paid to pharmacies, not to this prescriber.
Other transplant hepatology in Nashville
- Manhal IzzyNashville$25K
- Ashley SpannNashville$21K
- Suzanne SharptonNashville$2K
- Roman PerriNashville$2K
- Hannah KimNashville$502
- Jiten KothadiaMemphis$6K
- Bindu BetapudiCollierville$881
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.